FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LOUNGERS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. “This novel approach is part of Vera’s broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we treat patients suffering from a variety of B cell mediated diseases. We plan to leverage our research, translational medicine, clinical development...

Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceutical leadership with addition of Alzheimer’s radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months Company to host conference call on January 13, 2025, at 8:30 AM EST BEDFORD, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Life Molecular Imaging...

VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE: MEC, OTC:MECPF, FRA:92T) (the “Company” or “Mustang”) is pleased to announce the acquisition of the Königsstuhl Project, a 5,228 hectare property located in the Eastern Athabasca Basin in northern, Saskatchewan. Secured through cost-effective staking, the Königsstuhl Project adds five 100% owned mineral claims to Mustang’s expanding portfolio of promising uranium assets in one of the world’s premier mining districts. Project Highlights:Location: The project is located approximately 25 kilometers northwest of Cameco’s McArthur River Mine and 45 kilometres southwest of Cameco’s Cigar Lake Mine. Adjacent property mineralization (see Figure 1):Drill hole WMA-010 intersected 0.29% U3O8 over 0.5 m from 881.3-881.8 m, with anomalous Pb, V, Co,...

Elis announces the acquisition of Wäscherei Bodensee in Switzerland Saint-Cloud, 10 January 2025 – Elis, the global leader in circular services at work, today announces the acquisition of 100% of Wäscherei Bodensee AG in Switzerland. The company, which operates two laundries in the central and eastern region of the country, offers rental-maintenance services in flat linen, mainly for Healthcare (hospitals and nursing homes) and Hospitality customers. The company currently employs 220 people, and the management team will remain in place and will continue to grow the business. In 2024, Wäscherei Bodensee delivered c. €27 million revenue; the acquisition will be consolidated in the financial statements from January 1, 2025. This new acquisition will strengthen the Elis network in Switzerland and expand the Healthcare customer portfolio...

CLEARFIELD, PA and STROUDSBURG, PA, Jan. 10, 2025 (GLOBE NEWSWIRE) — CNB Financial Corporation (Nasdaq: CCNE) (“CNB”), parent company of CNB Bank, and ESSA Bancorp, Inc. (Nasdaq: ESSA) (“ESSA”), parent company of ESSA Bank & Trust (“ESSA Bank”), jointly announced today that they have entered into a definitive agreement pursuant to which ESSA will merge with and into CNB, and ESSA Bank will merge with and into CNB Bank. The combined company is expected to have approximately $8 billion in total assets, $7 billion in total deposits, and $6 billion in total loans. The transaction consideration is all common stock and is presently valued at approximately $214 million in the aggregate, or approximately $21.10 per ESSA share, based upon the 10-day volume weighted average stock price (VWAP) of $24.69 for CNB common stock as of January...

PHOENIX, Jan. 10, 2025 (GLOBE NEWSWIRE) — Diamond Lake Minerals, Inc. (OTC: DLMI) has acquired the highly regarded Solutions™ Naturopathic & SoftWave Acupuncture Clinics in Arizona. Led by the esteemed Dr. Steven Ehrlich, Solutions™ has become a trailblazer in holistic healthcare by integrating state-of-the-art SoftWave technology with a deeply personalized approach to wellness. This acquisition represents DLMI’s commitment to revolutionizing healthcare by offering non-invasive, drug-free pain management solutions and a clear path to vitality and longevity for patients across the United States.Leveraging Advanced SoftWave Technology to Heal Naturally The primary aim of this acquisition is to incorporate Solutions™’ innovative SoftWave technology into a scalable clinic model, enabling DLMI to bring effective,...

YOQNEAM, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers, unified communications (UC) analytics for enterprises as well as enterprise messaging solutions, today announced that it has signed a definitive agreement to acquire Aurenz GmbH (aurenz), a leading provider of UC analytics and call accounting solutions in Germany. Founded in 1983, aurenz maintains a leading position in the field of call accounting and in recent years in UC analytics. aurenz solutions provide essential added value for unified communication systems, easily and quickly integrating into every UC implementation. aurenz prides itself on delivering outstanding service to ensure seamless installations...

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years Simplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a $3 billion share repurchase program; $2 billion of shares intended to be repurchased in 2025 subject to market conditions Maintain significant capacity for new royalty transactions and remain committed to mid-single digit percentage annual dividend growth and investment grade credit rating Royalty Pharma to host investor call today, Friday, January 10, 2025 at 8:30am ETNEW YORK, Jan. 10, 2025...